REUTERS: Drug developer Neurotrope Inc's shares tumbled nearly 80per cent on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study.
This is the second time in just over two years that the treatment – Bryostatin-1 – failed to meet its targets, raising questions about the drug's future. (https://reut.rs/2kCiDyh)
The treatment, Bryostatin-1, did not show any significant difference in patients after 13 weeks compared with those on placebo, the company said on Monday.
Neurotrope said it intends to conduct a complete review of the data to determine next steps in the treatment's development.
Alzheimer's disease, which affects parts of the brain that control thought, memory and language, is a progressive condition that could seriously disrupt a patient's ability to carry out daily activities.
Several drugmakers such as Eli Lilly, AstraZeneca Plc, Roche AG, Pfizer Inc, Merck and Co Inc and Johnson and Johnson have all pre